Evidence map›Paper›PMID 40542273›Full record

ArticleProstate cancer and prostatic diseases2026

Case series exploring hormonal sensitivity in prostate cancer patients harboring the germline African-ancestry HOXB13 X285K variant.

Mayuko Kanayama, Emeline Colomba, Yusra Shao, Sarah M Nielsen, Edward D Esplin, Changxue Lu, William B Isaacs, John C Henegan, Elisabeth I Heath, Jun Luo and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mayuko KanayamaDepartment of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-1947-6311
Emeline ColombaDepartment of Molecular Cancer Genetic, University Hospital of Martinique, Fort de France, France.
Yusra ShaoKarmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA.
Sarah M NielsenLabcorp (formerly Invitae Corp.), San Francisco, CA, USA.
Edward D EsplinLabcorp (formerly Invitae Corp.), San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-9205-3756
Changxue LuDepartment of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-7565-8796
William B IsaacsDepartment of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
John C HeneganDepartment of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
Elisabeth I HeathMayo Clinic Comprehensive Cancer Center, Rochester, MN, USA.
Jun LuoDepartment of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jluo2@jhmi.edu.ORCID http://orcid.org/0000-0002-1414-473X
Régine MarlinDepartment of Molecular Cancer Genetic, University Hospital of Martinique, Fort de France, France. regine.marlin@chu-martinique.fr.ORCID http://orcid.org/0000-0001-7580-2997
Emmanuel S AntonarakisDepartment of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA. anton401@umn.edu.ORCID http://orcid.org/0000-0003-0031-9655

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecently, a germline HOXB13 variant, X285K was identified as a risk factor for prostate cancer in men of African ancestry. While this variant is likely associated with more aggressive prostate cancer, there has not yet been an in-depth clinical description of individual patients carrying this variant and their response to systemic therapies.

methodsWe studied six cases of germline X285K carriers with metastatic hormone-sensitive prostate cancer to characterize their hormonal sensitivity or resistance.

conclusionsLongitudinal outcome analysis indicates that patients carrying X285K generally show favorable responses to therapies targeting the androgen receptor (AR), a finding that requires confirmation.

Indexed as

Antineoplastic Agents, HormonalGerm-Line MutationHomeodomain ProteinsProstatic NeoplasmsAgedDrug Resistance, NeoplasmHumansMaleMiddle AgedReceptors, AndrogenAntineoplastic Agents, HormonalHomeodomain ProteinsHOXB13 protein, humanReceptors, Androgen

Identifiers

PMID40542273

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.